Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 18/20 | 0.50 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359686 | 1.00 | IRAK4 (0.50) | IRAK4MAP3K7SYKAURKAFLT3 | |
| SCHEMBL29638683 | 0.84 | IRAK4 (0.49) | IRAK4MAP3K7SYKAURKAFLT3 | |
| SCHEMBL357906 | 0.84 | IRAK4 (0.49) | IRAK4MAP3K7SYKAURKAFLT3 | |
| SCHEMBL30808056 | 0.80 | IRAK4 (0.49) | IRAK4MAP3K7SYKAURKAFLT3 | |
| SCHEMBL358109 | 0.80 | IRAK4 (0.58) | IRAK4MAP3K7SYKAURKAFLT3 | |
| SCHEMBL19073149 | 0.77 | IRAK4 (0.46) | IRAK4MAP3K7SYKAURKAFLT3 | |
| SCHEMBL30808061 | 0.75 | IRAK4 (0.53) | IRAK4MAP3K7SYKAURKAFLT3 | |
| SCHEMBL27185462 | 0.73 | DAO (0.40) | IRAK4AURKA | |
| SCHEMBL358315 | 0.72 | SYK (0.52) | IRAK4SYKIRAK1 | |
| SCHEMBL7114666 | 0.71 | KDM4E (0.48) | IRAK4IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239963-A | Compounds as eIF4E inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-113039182-B | Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment | 伊文蒂瓦公司 | 2024-02-20 | — | — | CN | disclosed |